Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant Long-Term Studies Prior To Approval Should Not Be Required, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Psychopharmacologic Drugs Advisory Committee finds that the agency’s proposed requirement for long-term data would delay drug marketing.

You may also be interested in...



Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns

Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data

Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns

Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data

FDA Requests Adult Antidepressant Suicidality Data

The agency's review of adult suicidality data will take at least a year to complete, FDA says in a Public Health Advisory. Manufacturers of antidepressants are being asked to review all placebo-controlled trials in adult patients using methodology similar to that used to analyze suicidality in pediatric trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS061154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel